2021 PDA Advanced Therapy Medicinal Products Conference
Registration Options
Individual Registration
Group Registration
Program Highlights
Now fully virtual! Don't miss out on the new and exciting session added this year: End-User Perspective.As part of PDA’s ongoing commitment to the future of the pharmaceutical industry, the Program Planning Committee would like to warmly invite you to join us for the 2021 PDA Advanced Therapy Medicinal Products (ATMP) Conference on 26-27 October.
The aim of this 2-day event is to support all stakeholders that are involved in the development and commercialization of novel and effective cell and gene and tissue therapies.
This year’s theme of Clearing the Hurdles and Winning the Race to Save Lives puts a spotlight on solutions rather than strictly the challenges associated with cell-based medicines. This year we have added a view from the other side of ATMP manufacturing. Hear from medical experts who are on the frontline and how they navigate the various challenges and roadblocks. We also added a hot topic session on hiring and job retention to help understand what are the motivating factors of trained employees for staying or leaving.
The agenda includes sessions on both early and late product lifecycle management with an emphasis on risk assessment and tech transfer, end-to-end CM&C and its vital role in safeguarding product quality and process consistency, the question of investing internally or externally to meet manufacturing capacity, regulatory updates and what needs to improve to get more life-saving products from clinical trials to commercialization, and lessons learned from the pandemic on supply chain management.
The conference will be a virtual event. The live plenary sessions including Q&A will provide engaging discussions.
The Scientific Program Planning Committee
At the completion of this conference, participants will gain skills to:
- Understand the roadblocks and hurdles experienced by medical professionals and how they balance patient safety and manufacturing lead times
- Anticipate and plan in early product lifecycle management leading to more successful clinical trials
- Monitor the process control strategy and manage process changes in late product lifecycle management
- Identify opportunities to leverage the lifecycle approach including risk assessments and tech transfer
- Understand the role of clinical laboratories and the need for rapid release strategies and analytical development as part of the CM&C for ATMPs
- Identify key regulatory hurdles and areas that slow down development & product release
- Leverage lessons learned for managing the supply chain during a crisis
- Determine when to make vs buy when scaling-up or scaling-out
Contact
Program Inquiries
Exhibition/Sponsorship Inquiries
Training Course Inquiries
Registration Customer Care
Standard Pricing
Standard Member Price
$1,436GovernmentMember Only
$630
Health AuthorityMember Only
$630
Early Career ProfessionalMember Only
$718
StudentMember Only
$252
AcademicMember Only
$630
Non-Member
$1,687
GROUP REGISTRATION DISCOUNT: Register 3 people from the same organization as a group (at the same time) for the event and receive the 4th registration free. Other discounts cannot be applied.
GENERAL TERMS AND CONDITIONS: PDA will send you a confirmation letter within one week of payment being received. You must have this confirmation letter to be considered enrolled in a PDA event. If you have submitted a purchase order or requested an invoice, please be advised that a credit card guarantee is needed. PDA reserves the right to modify the material or speakers/trainers without notice or to cancel an event. If an event is cancelled, registrants will be notified by PDA immediately and will receive a credit (registration fee paid). PDA will not be responsible for any costs incurred by registrants due to cancellation. Please note that the attendee list is shared with attendees, trainers, and exhibitors and may be used to follow up on specific areas of interest after the event. Video, photo, and audio recordings are prohibited at all PDA events.
CANCELLATION: If a cancellation request is received 30 days before the event, a credit (registration fee paid minus a 200.00 USD/EUR processing fee) will be given. No credits will be given for cancellation requests received less than 30 days before the event. Cancellation requests must be emailed to [email protected].
Day 1
Tuesday, 26 October
|
09:00 – 10:10 | Plenary 1: End User Perspective |
| Moderator: MaryEllen Usarzewicz, BMS The primary focus for ATMPs tends to be on the manufacturing process and a quick return of the product to the patient. Have you ever wondered what happens in between the manufacturing process and delivery of the product to the patient? This session will allow you to hear firsthand from medical experts who are on the frontline and who liaise between the manufacturing sites, the health care providers, and the patients. Join us as they share their unique role and the various roadblocks and challenges, they encounter in the world of ATMPs. |
|
Voice of the Treating Physician |
Break
|
10:30 – 12:00 | Plenary 2: Product Lifecycle Management for ATMPs - Early |
| Moderator: David Geoghegan, Tmunity Managing ATMP Products through the clinical development process and into commercialization presents unique challenges. As more of these products make clinical progress, identifying the potential solutions will help technical teams anticipate and plan for successful product development. The goals of this session are to discuss those challenges and approaches to handling them. |
|
Early Phase Considerations Qualifying Suppliers of Cellular Starting Materials: Accreditation Alone is Not Enough Analytical Testing Strategies for Early Phase CAR-T Products Q&A |
Break
|
12:20 – 13:50 | Plenary 3: Product Lifecycle Management for ATMPs - Later |
| Moderator: Darius Pillsbury, ValSource On the heels of the commercialization of multiple ATMPs globally (including many within this past year) and the quickly increasing number of ATMPs rapidly moving through development, organizations are finding themselves faced with the many hurdles presented in the later stages of the product lifecycle. In this session many of these challenges of the later stages of the product lifecycle are presented and solutions are provided by the speakers. |
|
CMC Recommendations for Late-Stage Development of Cell & Gene Therapy Products Quality Risk Management for Cross Contamination of ATMPs Learnings from Manufacturing Commercial Axicabtagene Ciloleucel: Process Improvement Perspectives Q&A |
Break
|
14:10 – 16:10 | Plenary 4: End to End |
| Moderator: Dayue Chen, Genentech It is universally recognized that CM&C for CGT products is significantly more challenging in comparison to traditional drug products. As a result, a comprehensive strategy is critical to ensure effective end-to-end control throughout the manufacturing process. This session provides some illustrations of the end-to-end manufacturing and its vital role in safeguarding product quality and process consistency. |
|
Key Considerations for the Development of Commercially Viable Cell-based Therapies What Clinical Labs Need to Know for Testing ATMP Products ATMP Control Strategies Require New Thinking and New Approaches Q&A |
Day 2
Wednesday, 27 October
|
08:30 – 09:30 | PDA ATMP Interest Group Update |
| Moderator: Darius Pillsbury, ValSource This session will provide an update on the latest projects from the PDA ATMP Interest Group. |
|
09:50 – 11:20 | Plenary 5: Regulations |
| Moderator: Lori Daane, bioMerieux This session will explore the current and future trends in cell and gene therapy and how they impact guidelines and regulations. Companies must understand and navigate the shifting regulatory landscape of global regulatory requirements in order to advance more life-saving therapies through clinical trials to commercialization. This session will address many of these challenges and will present solutions to help regulations keep pace with the science. |
|
Evolving regulations and What Needs to be Done to Keep Pace with the Science of ATMPs Preparing for an Evolving Regulatory Cell and Gene Therapy Landscape USP Expert Committee Update on USP Chapters 72 and 73 |
Break
|
11:40 – 13:10 | Plenary 6: Risk Assessment/Tech Transfer |
| Moderator: Katherine Giacoletti, Merck & Co., Inc. Successful technology transfer for ATMPs can be complicated by a number of factors, including material safety considerations, high manufacturing variability, availability of material during early phases for process and analytical development runs, necessary process changes to facilitate scale-up, and the transition of a product from an academic development setting often used in early clinical phases into a GMP manufacturing environment for later stage development. This session will dive into some of these challenges and possible solutions, such as Quality Risk Management tools, effective CDMO-sponsor collaboration, and leveraging the Lifecycle Approach to Process and/or Analytical Validation. |
|
Lifecycle Approach to Analytical Method Development & Validation for Gene Therapies Risk Assessments to Facilitate Transfer of Analytical Methods Methods for Specification Development with Small Sample Sizes Q&A |
Break
|
13:30 – 15:00 | Plenary 7: Supply Chain Management |
| Moderator: MaryEllen Usarzewicz, BMS Supply Chain Management for ATMPs is always a challenge. The COVID-19 pandemic further complicated the challenge. Dealing with issues such as PPE and consumable shortages as well as contingency planning and emergency preparedness are topics that will be discussed during this session. Ultimately, the show must go on to ensure a consistent delivery of treatments to our patients. |
|
Navigating Cell Therapy Supply Chain Complexities During the COVID-19 Pandemic What Do You Mean We Are Out of Shoe Covers? Q&A |
Break
|
15:20 – 16:50 | Plenary 8: Manufacturing Network |
| Moderator: Peter Makowenskyj, G-CON Manufacturing With companies of all sizes rapidly advancing their internal pipelines in the ATMP space there is a major lack of capacity to meet current and future demand. Companies large and small are faced with many difficult questions to address how they advance through the clinics and eventually to commercial manufacturing. We will look at some of these difficult to answer questions and evaluate what has been done within this space to leverage lessons learned. |
|
Clinical Phase Manufacturing Strategy: Critical Considerations & Challenges in Cell Therapy Interest in Intensification to a Factory of the Future Q&A |
Become a Sponsor
Interested in becoming a sponsor? Learn about opportunities and benefits.
Request InformationBecome an Exhibitor
Interested in becoming an exhibitor? Learn about opportunities and benefits.
Request InformationPLEASE READ PDA is not affiliated or contracted with any outside hotel contracting company. If someone other than PDA or the PDA chosen hotel contacts you suggesting that they represent any PDA event, they do not. It is PDA's recommendation that you book your hotel directly through the official PDA chosen hotel that is listed on our web site.